Literature DB >> 2165104

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus).

B Meignier1, B Martin, R J Whitley, B Roizman.   

Abstract

The genetically engineered herpes simplex virus strains R7017 and R7020 were tested in owl monkeys (Aotus trivirgatus) previously shown to model herpetic diseases of immunocompromised patients and neonates. In contrast to the lethal disease seen in monkeys receiving 100-1,000 plaque-forming units (pfu) of wild-type virus, inoculation of greater than or equal to 10(6) pfu of recombinant viruses produced local lesions and viral shedding but not disseminated disease. Latent recombinant viruses were recovered from some ganglia innervating the sites of inoculation. Monkeys protected from lethal infection with wild-type virus exhibit recurrent lesions that increase in frequency and severity after total lymphoid gamma irradiation (TLI). In contrast, monkeys immunosuppressed by TLI and inoculated with R7020 could not be differentiated from irradiated controls with respect to morbidity or mortality. Moreover, the virus was not transmitted from immunosuppressed infected females to normal male cage mates.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2165104     DOI: 10.1093/infdis/162.2.313

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  32 in total

1.  Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus.

Authors:  C G Murphy; W T Lucas; R E Means; S Czajak; C L Hale; J D Lifson; A Kaur; R P Johnson; D M Knipe; R C Desrosiers
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 2.  Herpes simplex viruses: is a vaccine tenable?

Authors:  Richard J Whitley; Bernard Roizman
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

3.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

4.  Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.

Authors:  Sita Awasthi; Elizabeth E Zumbrun; Huaxin Si; Fushan Wang; Carolyn E Shaw; Michael Cai; John M Lubinski; Shana M Barrett; John W Balliet; Jessica A Flynn; Danilo R Casimiro; Janine T Bryan; Harvey M Friedman
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

5.  Attenuated herpes simplex virus 1 blocks arterial apoptosis and intimal hyperplasia induced by balloon angioplasty and reduced blood flow.

Authors:  Christopher L Skelly; Amito Chandiwal; James E Vosicky; Ralph R Weichselbaum; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-12       Impact factor: 11.205

6.  Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.

Authors:  Sita Awasthi; John M Lubinski; Carolyn E Shaw; Shana M Barrett; Michael Cai; Fushan Wang; Michael Betts; Susan Kingsley; Daniel J Distefano; John W Balliet; Jessica A Flynn; Danilo R Casimiro; Janine T Bryan; Harvey M Friedman
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

Review 7.  The challenge of developing a herpes simplex virus 2 vaccine.

Authors:  Lesia K Dropulic; Jeffrey I Cohen
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

8.  A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine.

Authors:  Elizabeth E Brittle; Fushan Wang; John M Lubinski; Ralph M Bunte; Harvey M Friedman
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

9.  Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine.

Authors:  Sita Awasthi; John M Lubinski; Harvey M Friedman
Journal:  Vaccine       Date:  2009-09-15       Impact factor: 3.641

10.  Imaging of lymph node micrometastases using an oncolytic herpes virus and [F]FEAU PET.

Authors:  Peter Brader; Kaitlyn Kelly; Sheng Gang; Jatin P Shah; Richard J Wong; Hedvig Hricak; Ronald G Blasberg; Yuman Fong; Ziv Gil
Journal:  PLoS One       Date:  2009-03-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.